Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV, a foreign private issuer, for the month of December 2023. The report, dated December 21, 2023, incorporates by reference a press release issued on December 19, 2023 (Exhibit 99.1). The filing serves to disclose material information to U.S. investors pursuant to Rule 13a-16 under the Securities Exchange Act of 1934. Note: The request metadata references "Lakefront Biotherapeutics NV," but the filing text explicitly identifies the registrant as Galapagos NV.
Key Financial Metrics
The provided filing text does not contain specific financial data. It is a procedural report incorporating a press release by reference. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this document.
Material Changes
The filing text does not detail specific material changes in financial performance or operations. It solely references the issuance of a press release on December 19, 2023, the content of which is not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, or specific risk factors. It notes that quotes from Jeevan Shetty included in the attached press release are not incorporated by reference into the Company's Registration Statements on Form S-8.
Investor Verification Checklist
- Verify the actual content of the press release dated December 19, 2023 (Exhibit 99.1), as the summary text only references its existence.
- Confirm the correct registrant name is Galapagos NV, not Lakefront Biotherapeutics NV.
- Review the incorporated Form S-8 Registration Statements for historical context on equity plans.
- Check subsequent filings for the specific financial or operational details announced in the December 19 press release.